Recent data presented at the 26th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America in Grapevine, Texas, suggest that testosterone replacement therapy (TRT) does not increase the risk of hearing loss in men with hypogonadism. The findings provide reassurance for patients and clinicians concerned about potential auditory side effects of TRT.
Dr. Muhammed A. Moukhtar Hammad, MBBCh, from the University of California, Irvine, discussed the study in an interview with Urology Times®, highlighting the study’s methodology and implications for clinical practice.
Study Design and Patient Population
The investigation utilized a retrospective matched cohort design, drawing on data from a global electronic health record (EHR) network. Researchers identified 107,908 men who received TRT and compared them with an equal number (110,908 men) who had a diagnosis of hypogonadism but never received testosterone therapy.
Importantly, all participants had no prior history of ear disorders, allowing the study to focus on incident cases of hearing loss attributable solely to TRT exposure. The mean follow-up period was 4.45 ± 3.78 years for TRT users and 4.32 ± 3.79 years for non-users, providing a substantial timeframe to capture potential auditory changes.
Key Findings on Hearing Loss Risk
Analysis of the matched cohort revealed similar rates of ear disorders between the two groups. Specifically, 3.14% of men receiving TRT developed hearing issues, compared with 3.279% of men who never used TRT. Statistical testing indicated that this difference was not significant (P = 0.0669; SD = 0.0079).
These results suggest that TRT does not confer additional risk for hearing loss in men with hypogonadism, countering previous concerns that testosterone supplementation might affect auditory function.
Clinical Implications
Dr. Hammad emphasized that the findings provide important reassurance for clinicians prescribing TRT, particularly for long-term therapy in hypogonadal men. While TRT is commonly used to address low testosterone symptoms such as fatigue, reduced libido, and mood disturbances, concerns about rare but potentially serious side effects like hearing loss can influence patient adherence.
The study’s large sample size and use of matched controls strengthen the reliability of these findings, underscoring that TRT appears safe from an auditory perspective over several years of therapy.
Conclusion
This research contributes to the growing body of evidence supporting the safety profile of testosterone replacement therapy, highlighting that concerns regarding hearing loss may be largely unfounded in hypogonadal men. Future studies could explore other potential long-term sensory effects, but current evidence supports continued use of TRT without heightened auditory risk.
Related topics
